8-K 1 a52012759.htm SYNLOGIC, INC. 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 15, 2019
SYNLOGIC, INC.
(Exact name of registrant as specified in its charter)
Delaware
  
001-37566
  
26-1824804
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
 
  
(IRS Employer
Identification No.)
 
301 Binney St., Suite 402
Cambridge, MA
  
 
02142
(Address of principal executive offices)
  
(Zip Code)
Registrant’s telephone number, including area code: (617) 401-9975
 Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
SYBX
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01. Regulation FD Disclosure.

On July15, 2019, Synlogic, Inc. (“Synlogic”) will conduct an investor webcast summarizing top-line clinical data from expansion cohorts of patients with phenylketonuria (PKU) in its Phase 1/2a clinical trial to evaluate its product candidate SYNB1618, which is being developed for the management of PKU. A copy of the presentation is furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On July 15, 2019, Synlogic issued a press release announcing top-line clinical data from expansion cohorts of patients with PKU in its Phase 1/2a clinical trial to evaluate its product candidate SYNB1618, which is being developed for the management of PKU.

The full text of Synlogic’s press release regarding the announcement is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01  Financial Statements and Exhibits.

(d)            Exhibits



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  SYNLOGIC, INC.  
       
Date:  July 15, 2019
By:
/s/  Todd Shegog  
  Name:
  Todd Shegog  
  Title:
  Chief Financial Officer